GskGSK

GSK’s TB vaccine candidate may sound like the kind of headline-grabbing breakthrough that could redefine the company’s pipeline, but the reality is more sobering: the vaccine remains in Phase II/III trials, with no revenue line attached. The news wires buzzed this week with a ‘new manufacturing agreement’ that GSK frames as a step toward ‘global access,’ but the filing language stops short of promising commercialisation or even a clear timeline. The company’s press releases lean hard on imagery-futuristic labs, pristine production lines-while the clinical-trial pages quietly note that the programme is still years from delivering a product that patients will actually use. (source: GSK, Press releases | GSK, https://www.gsk.com/en-gb/media/press-releases/)

GSK describes itself as a company ‘unlocking the science of the immune system,’ but the numbers suggest it’s more accurate to say the company is optimising cash flows from products that already exist. The 2025 Annual Report on Form 20-F lists four core therapeutic areas-respiratory, immunology and inflammation, oncology, and HIV (via ViiV Healthcare)-but the revenue table reveals a familiar pattern: respiratory products account for roughly a third of sales, while oncology and HIV contribute smaller, volatile slices. The glossy ‘vaccine laboratory’ photos are designed to make you feel confident in the science, but the balance sheet is what matters: GSK generated £9.2bn in revenue in 2025, down 3% from 2024, with operating profit of £2.1bn, a 12% drop. The company’s ‘responsible business’ language doesn’t change the fact that the cash engine is sputtering. (source: GSK, 2025 Annual Report on Form 20-F, https://www.gsk.com/en-gb/investors/financial-reports/)

The filing also reveals that GSK’s free cash flow fell to £4.2bn in 2025 from £5.1bn in 2024, a decline that wasn’t offset by a drop in R&D (capex held steady at £1.1bn). The company’s dividend commitment-£0.90 per share-looks sustainable on paper, but the math tightens when you realise that the dividend is being funded in part by the same capital discipline that’s cutting free cash flow. The board’s buyback programme, announced with due solemnity, is calibrated to the cash that’s left after dividends and capex, not the other way around. (source: GSK, Responsible Business Report 2025, https://www.gsk.com/en-gb/investors/financial-reports/)

The London Stock Exchange route-LSE:GSK-shows a share price that’s been rangebound for years, with no clear catalyst in sight. The TradingView chart route doesn’t reveal magic levels, but it does show a stock that’s neither collapsing nor soaring, just drifting in the middle of a long, flat channel. The market is pricing in the absence of surprises: no blockbuster drug launch, no regulatory breakthrough, no sudden uptick in respiratory infections. The company’s clinical-trial pages are full of ‘representative studies’ designed to reassure regulators and clinicians, but they don’t translate into near-term revenue. The ‘provision of unapproved medicines’ page exists to cover the rare cases when a desperate doctor asks for a drug outside its licence, but it’s not a growth engine. (source: TradingView, LSE:GSK route, https://www.tradingview.com/chart/?symbol=LSE%3AGSK)

The tension in the file isn’t about whether GSK will survive-it’s about whether the company can grow again. The respiratory franchise, once a cash cow, is under pressure from generics and pricing reforms. Oncology and HIV are volatile, with clinical-trial outcomes that swing wildly on data readouts. The TB vaccine, for all its noble intent, is a long-term punt with no guarantee of success. The board’s rhetoric is polished, but the filings tell a plainer story: GSK is a mature cash engine with limited upside unless something truly new breaks through the pipeline. The question isn’t whether the company will pay dividends-it’s whether those dividends will grow. (source: GSK, Pipeline | GSK, https://www.gsk.com/en-gb/innovation/pipeline/)